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The EULAR recommendations for the management of fibromyalgia are based on more than 100 reviews 
and meta-analyses of individual therapies and medicines.1 Thus, the quality of the evidence in making 
recommendations on effectiveness and efficacy is generally very high. In contrast, there is little 
published research evaluating models of care for patients with fibromyalgia, and thus this aspect of the 
recommendations is based on expert opinion of the working group, which was drawn from throughout 
Europe and across specialties. 
Mercieca and Borg2 provide an alternative model of care based on the practice within their own 
hospital. Their study and evaluation has not been published, and therefore there is not sufficient detail 
provided for us to evaluate it. However, there are features of the pathway outlined that are unappealing 
and directly contradict the EULAR recommendations. Their first-line approach is prescription of 
ŵediĐatioŶ ;stated as ͚if ƌeƋuiƌed͛Ϳ, aŶd this happeŶs eveŶ ďefoƌe the patient is educated about the 
condition. Many clinicians and patients would find this unacceptable. Their local pathway and the EULAR 
recommendations do agree on the important role of stratified care including for psychological 
comorbidities. 
Nevertheless, it does highlight the need for more research around models of care for fibromyalgia 
patients, so that we can identify which deliver better outcomes at an affordable cost and are acceptable 
to patients. 
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